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satisfaction of inpatient and outpatient setting are inﬂuenced by
the different variables. The disease cure is enough to interpreter
the whole satisfaction in inpatient. But in outpatient setting,
other than the variable of symptoms relieved, there are more
variables inﬂuenced the patient satisfaction. However, the other
medical process such as waiting time for several stages, patient
privacy, patient right, informed consent and so on did not inﬂu-
ence patient satisfaction.
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OBJECTIVES: The PROLabels database (www.mapi-prolabels.
org) was developed to provide easy access to Patient-Reported
Outcomes (PROs) included in approved labeling of products in
Europe and the USA. Two years after its launch, the coverage of
FDA labels has been extended to give a more comprehensive
image of the current use of PROs in clinical studies. METHODS:
In 2006, the database opened with drugs approved in Europe
through the centralized procedure established by the EMEA in
January 1995 and with New Molecular Entities (NME)
approved in the USA since January 1998. The extension project
focused on other chemical types approved by FDA (e.g. New
dosage form, New combination, etc.) and on NME approved
before 1998. Once a PRO claim was identiﬁed in a label, the drug
was added in PROLabels and the following information was
retrieved: the PRO claim, description of clinical studies support-
ing the claim, description of PRO endpoints and measures used,
pharmacological action of products and information source.
RESULTS: Updated ﬁgures resulting from this major extension
of PROLabels will be presented. These new ﬁgures will include
the number of drug products present in the database with the
FDA/EMEA distribution, the most represented therapeutic areas
(currently nervous system diseases: 27.8%, immune system dis-
eases: 20.6%, respiratory tract diseases: 16.5%, pathological
conditions, signs and symptoms: 14.9%, and mental disorders:
14.6%), and the most frequently measured PROs (currently
Signs and Symptoms followed by Health-Related Quality of Life
(HRQL)). Finally, any change in the rate of PRO data found
overall in FDA approvals will be checked. CONCLUSIONS:
This extension of the FDA coverage of the PROLabels database
allows a clearer picture of the use of PROs to assess patients’
treatment beneﬁt to be drawn. In addition, it facilitates the
examination of the discrepancies between the US and European
regulatory agencies.
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OBJECTIVES: Health locus of control (HLC) is associated with
health-related behaviors such as adherence and participation in
health screening. However, HLC among physicians may be dif-
ferent from that among the general public. It is important to
understand the potential gap in HLC between physicians and the
general public. The aim of the study included two steps: 1) to
evaluate item bias of the HLC scale between physicians and the
general public, and 2) to characterize HLC among physicians
compared to the general public. METHODS: Data for the
general public were obtained from the health diary study that
involved a random sample from a nationally representative
group of households in Japan. Physicians’ data were collected
from a web-based survey of Japanese physicians. Multi-group
structural equation modeling was used for examining item bias in
the Japanese version of the HLC scale (HLCS-J) between the two
groups. Differential item functioning (DIF), including uniform
and non-uniform types, were used for measuring item bias.
Dimensions with no uniform and non-uniform DIFs were then
compared using multiple linear regressions. RESULTS: Data on
the HLCS-J of 2194 people from the general public and 895
physicians were available. Uniform DIF was recognized for the
dimensions of internal, professional control and control by spiri-
tual powers. Chance and family control dimensions had no DIF.
Mean score for chance control (17.2) among physicians was
greater than that (14.9) among the general public (adjusted
p < 0.001), while mean score for family control (21.7) among
physicians was lower than that (22.1) among the general public
(adjusted p < 0.001). CONCLUSIONS: Our psychometric evalu-
ation of the HLCS-J indicates item bias in the dimensions of
internal, professional control and control by spiritual powers.
Physicians believe that chance has a greater impact but family
control has a lesser impact on health than do members of the
general public.
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OBJECTIVES: The VAS is a common response scale in PRO
questionnaires, which are used in multinational studies from
which data is pooled. This study was designed to evaluate the
suitability of VAS for use in different international settings,
speciﬁcally to evaluate the cognitive processes and challenges
occurring when respondents from a range of countries/cultures
complete VAS. METHODS: Adults were recruited from: UK;
Mexico; Spain; Malaysia; India; South Africa, with approxi-
mately 50:50 males/females and higher/lower education split.
Each completed four VAS followed by a cognitive debrieﬁng
interview, once before and once after receiving standardized
instructions. RESULTS: Thirty-seven lay persons were inter-
viewed across 6 countries, mean age was 46  19; 51.4% were
male. Several respondents commented on the unfamiliar style of
the VAS. Some reported the anchors as inappropriate/ambiguous,
impeding scale completion, or that anchor wording caused them
to avoid scale extremities. Respondents noted the lack of inter-
mediate markers on the VAS, therefore having to rely on ‘guess-
work’: most used quantitative rather than qualitative strategies
when deciding where to place their mark. Some had concerns
that ‘guesswork’ led to inaccurate responses. British and Spanish
respondents used principally quantitative methods whereas Zulu
speakers relied more on qualitative techniques. Respondents
from Malaysia, South Africa and India were more inclined to
report challenges; Zulu and Tamil speakers completed the VAS in
the least conventional way. CONCLUSIONS: The study provides
substantial evidence that the use of VAS in different international
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